For a second time, the US Food and Drug Administration has rejected a submission from Merck & Co (NYSE: MRK) for approval to market a chronic cough medication.
The agency issued a Complete Response Letter (CRL) in early 2022, demanding more data on efficacy in relation to the oral P2X3 receptor antagonist.
Now Merck has revealed another CRL has been issued, despite positive results from the COUGH-1 and COUGH-2 studies, both of which met their primary endpoints.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze